午啪啪夜福利无码亚洲,亚洲欧美suv精品,欧洲尺码日本尺码专线美国,老狼影院成年女人大片

1、北京XX醫療科技有限公司為廣大癌癥患者提供安全有效的治療方案：CAR-T用于晚期癌癥治療的CAR-T療法:CAR-T therapy for late-stage cancers:白血病 Leukemia淋巴瘤 Lymphoma肺癌 Lung cancer肝癌 Hepatocellular carcinoma胰腺癌 Pancreatic cancer膠質瘤 Glioma/Neuroblastoma產品/服務 Products/Service FDA:Break Through Therapy 革命性的應答率 Revolutionary response rate未來的癌癥治療終極策略：CAR-2、TFuture cure to cancer:Chimeric Antigen Receptor-T cellPBMC collectionT cell isolationActivationCAR infectionQCInjection1 Leukemia.2009.23,912918.2 Lancet.2015 Feb 7;385(9967):517-28.最暢銷的抗癌藥物 1Best anti-cancer medicineCAR-T 2需求：填補市場空白 Market vacancy90%2.7%復發白血病治療的完全緩解率 Remission rate of refractory l3、eukemia1:專利申請號(Patent No.)201380010725.2 2:專利申請號(Patent No.)201280027682.412對癌細胞的殺傷率比友商高1倍以上Killing rate of cancer cells doubles competitors市值：31 億美元Market Value:$3.1 billion市值：2561 億美元Market Value:$256.1 billionXXImmunochinaApoptosis rate of cancer cellsNorvatis對白血病小鼠具有顯著療效Remarkable efficacy on le4、ukemic miceParalysis rate(%)Overall survival(%)DayDay對淋巴癌小鼠具有顯著療效Remarkable efficacy on lymphoma-bearing miceTumor volume(mm3)Overall survival(%)DayDay指標 index國外某著名藥企 overseas competitorXXImmunochina細胞存活 viability70%95%CD8陽性率 EXP rate80%90%轉導效率 efficiency20%30%內毒素含量 endotoxin3.5EU/mL0.01EU/mL真菌含量 fu5、ngus陰性陰性HIV-1 p2410pg/mL5pg/mLVSV-G DNA陰性陰性BSA1ug/mL0.1ug/mL領先的安全性和穩定性評價體系Leading evaluation system of safety and stability商業模式 Business model中心實驗室 Central lab三甲醫院 Class A hospital小醫院小醫院三甲醫院Class A hospital小醫院小醫院三甲醫院Class A hospital小醫院小醫院與頂尖醫院長期合作Cooperate with top-class hospitals in the long run直接向6、醫院收費Directly charge hospitals優質低價Provide high quality service at a reasonable price慈善醫療Charity treatmentQ3/2015Q4/2015Q1/2016Q2/2016提交8項專利Submission of 8 patents新適應癥的細胞實驗Cell experiments of new CARs啟動單中心臨床試驗Initiation of clinical trial啟動多中心臨床試驗Initiation of multicenter clinical trial新適應癥的臨床前試驗Pre-cl7、inical studies on new CARs啟動新適應癥臨床試驗Initiation of clinical trials on new CARs拓展10家優質合作醫院10 hospitals完成臨床試驗Finish 1st clinical trial開展收費服務Commercialization時間表 Timetable亮點 HighlightsCAR-T療法是惡性腫瘤治療的重大突破CAR-T therapy is a breakthrough in treating malignant tumors.CAR-T療法是難治/復發白血病患者的希望CAR-T therapy is th8、e hope for leukemic patients.領先的CAR-T制備技術（對癌細胞殺傷率比友商高1倍以上）Leading technology of CAR-T(killing rate of cancer cells doubles the competitors)多種臨床前模型驗證療效Proven efficacy by various pre-clinical models完備的質量控制體系Complete QC system合伙人：清華博士+臨床醫生Partners:Ph.D.from Tsinghua Univ.&clinician行業經驗：I類抗癌新藥研發、III類醫療器械研發Expertise:R&D of anti-cancer medicine and medical equipment學術背景：癌癥生物學、分子生物學、臨床醫學Academic:cancer biology,molecular biology and clinical medicine創新能力：2015年內提交9項專利Innovation:9 patents in 2015團隊 TeamEvery cloud has a silver lining.